Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-10-24 | New | $13,109,494 | $13,109,494 | Other | 06b | SEC link |
| 2022-08-04 | New | $3,000,000 | $3,000,000 | Equity Only | 06b | SEC link |
| 2022-03-21 | New | $1,467,502 | $1,467,502 | Equity Only | 06b | SEC link |
| 2017-09-13 | New | $12,000,000 | $12,000,000 | Equity Only | 06b | SEC link |
| 2012-11-05 | New | $10,800,000 | $10,800,000 | Equity Only | 06 | SEC link |
| 2012-10-22 | New | $7,637,252 | $7,637,252 | Equity Only | 06 | SEC link |
| Name | Role |
|---|---|
| C. Evan Ballantyne | Executive |
| Steve Kanzer | Director |
| Jeffrey J. Kraws | Director |
| John Monahan | Director |
| Jeffrey Riley | Director, Executive |
| Steven A. Shallcross | Director, Executive |
| Joseph Sliman | Executive |
| Scott Tarriff | Director |
| Jeffrey A. Wolf | Director |